Enhanced Response of Acute Monocytic Leukemia Cells to Low-dose Cytarabine by 1,25-dihydroxyvitamin D3

Abstract

Low-dose cytarabine combined with differentiating or DNA hypomethylating agents, such as vitamin D compounds, is a potential regimen to treat acute myeloid leukemia (AML) patients who are unfit for high-intensity chemotherapy. The present study aimed to determine which subset of AML would be most responsive to low-dose cytarabine with the differentiating agent 1,25-dihydroxyvitamin D3 (1,25-D3). Here, firstly, cBioPortal database was used and we found out that vitamin D receptor (VDR) was highly expressed in acute monocytic leukemia (M5) and high VDR expression was associated with a poor survival of AML patients. Then, we confirmed that 1,25-D3 at clinical available concentration could induce more significant differentiation in acute monocytic leukemia cell lines (U937, MOLM-13, THP-1) and blasts from M5 patients than in non-monocytic cell lines (KGla and K562) and blasts from M2 patient. Finally, it was shown that the combination of 1,25-D3 and low-dose cytarabine further increased the differentiating rate, growth inhibition and G0/G1 arrest, while mild changes were found in the apoptosis in acute monocytic leukemia cell lines. Our study demonstrates that the enhanced response of acute monocytic leukemia cells to low-dose cytarabine by 1,25-D3 might indicate a novel therapeutic direction for patients with acute monocytic leukemia, especially for elderly and frail ones.

Keywords

low-dose cytarabine / 1,25-dihydroxyvitamin D3 / vitamin D receptor / acute monocytic leukemia

References

[1] SykesDB, KfouryYS, MercierFE, et al. . Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell, 2016, 167(1): 171-186 PMID: 27641501

[2] DohnerH, WeisdorfDJ, BloomfieldCD. Acute Myeloid Leukemia. N Engl J Med, 2015, 373(12): 1136-1152 PMID: 26376137

[3] KantarjianHM, ThomasXG, DmoszynskaA, et al. . Multicenter, randomized, open-label, phase HI trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol, 2012, 30(21): 2670-2677 PMID: 22689805 PMCID: 4874148

[4] Di FeboA, LaurentiL, FalcucciP, et al. . All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients. Am J Ther, 2007, 14(4): 351-355 PMID: 17667210

[5] ForghieriF, BigliardiS, QuadrelliC, et al. . All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature. Clin Case Rep, 2016, 4(12): 1138-1146 PMID: 27980750 PMCID: 5134148

[6] CaoH, XuY d, Necochea-CampionR, et al. . Application of vitamin D and vitamin D analogs in acute myelogenous leukemia. Exp Hematol, 2017, 50: 1-12 PMID: 28174131

[7] MarchwickaA, CebratM, SampathP, et al. . Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin D and vitamin D analogs. Front Oncol, 2014, 4: 125 PMID: 24904835 PMCID: 4034350

[8] CortesM, ChenMJ, StachuraDL, et al. . Developmental Vitamin D Availability Impacts Hematopoietic Stem Cell Production. Cell Rep, 2016, 17(2): 458-468 PMID: 27705794 PMCID: 5338633

[9] HarrisonJS, BershadskiyA. Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: a review of the literature. Leuk Res Treatment, 2012, 2012: 125 814

[10] KullingPM, OlsonKC, OlsonTL, et al. . Vitamin D in hematological disorders and malignancies. Eur J Haematol, 2017, 98(3): 187-197 PMID: 27743385

[11] Ferrer-MayorgaG, Gomez-LopezG, BarbachanoA, et al. . Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer. Gut, 2017, 66(8): 1449-1462 PMID: 27053631

[12] SrinivasanM, ParwaniAV, HershbergerPA, et al. . Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol, 2011, 123(l-2): 30-36 PMID: 20955794

[13] DitschN, TothB, MayrD, et al. . The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J Histochem Cytochem, 2012, 60(2): 121-129 PMID: 22108646 PMCID: 3351121

[14] GocekE, MarchwickaA, BaurskaH, et al. . Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. J Steroid Biochem Mol Biol, 2012, 132(3-5): 220-226 PMID: 22789609

[15] Int J Mol Sci, 2017, 18(3

[16] Sci Signal, 2013, 6269

[17] Cancer Discov, 2012, 25

[18] JensenHA, YourishHB, BunaciuRP, et al. . Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression. FEBS Open Bio, 2015, 5: 789-800 PMID: 26566473 PMCID: 4600856

[19] MartinoV, TonelliR, MontemurroL, et al. . Down-regulation of MLL-AF9, MLL and MYC expression is not obligatory for monocyte-macrophage maturation in AML-M5 cell lines carrying t(9;ll)(p22;q23). Oncol Rep, 2006, 151): 207-211 PMID: 16328057

[20] GuptaK, StefanT, Ignatz-HooverJ, et al. . GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. Cancer Res, 2016, 76(9): 2743-2753 PMID: 26964622 PMCID: 5563074

[21] BurkM, HeyllA, ArningM, et al. . Pharmacokinetics of high-dose cytarabine and its deamination product~ a reappraisal. Leuk Lymphoma, 1997, 27(3-4): 321-327 PMID: 9402329

[22] ShaoX, LiuY, LiY, et al. . The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARalpha/STAT1 axis. Sci Rep, 2016, 6: 24589 PMID: 27074819 PMCID: 4830980

[23] LaineyE, WolfrommA, SukkurwalaAQ, et al. . EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cell Cycle, 2013, 12(18): 2978-2991 PMID: 23974111 PMCID: 3875673

[24] WangM, LindbergJ, KlevebringD, et al. . Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia, 2017, 31(10): 2029-2036 PMID: 28167833 PMCID: 5629364

[25] ChienW, SunQY, DingLW, et al. . Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD. Leukemia, 2017, 31(3): 762-766 PMID: 27881871

[26] PollyP, HerdickM, MoehrenU, et al. . VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB J, 2000, 14(10): 1455-1463 PMID: 10877839

[27] GocekE, KielbinskiM, MarcinkowskaE. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS Lett, 2007, 581(9): 1751-1757 PMID: 17418144

[28] BaurskaH, KielbinskiM, BiecekP, et al. . Monocytic differentiation induced by side-chain modified analogs of vitamin D in ex vivo cells from patients with acute myeloid leukemia. Leuk Res, 2014, 38(5): 638-647 PMID: 24703772

[29] MarchwickaA, CebratM, LaszkiewiczA, et al. . Regulation of vitamin D receptor expression by retinoic acid receptor alpha in acute myeloid leukemia cells. J Steroid Biochem Mol Biol, 2016, 159: 121-130 PMID: 26969398

[30] HeroldN, RuddSG, LjungbladL, et al. . Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med, 2017, 23(2): 256-263 PMID: 28067901

[31] HarrisonJS, WangX, StudzinskiGP. The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts. Oncotarget, 2016, 7(24): 36 447-36 460

[32] WangZ, WangS, FisherPB, et al. . Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIPl in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation, 2000, 66(1): 1-13 PMID: 10997587

[33] LiH, KohKR, ToramotoT, et al. . Cytosine-arabinoside stimulates the capability of human marrow stromal cells to support normal hematopoiesis. Osaka City Med J, 2010, 56(2): 11-20 PMID: 21466125